BREVICON 21-DAY
LOE ApproachingNDAORAL-21TABLET
Approved
Dec 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 12h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BREVICON 21-DAY is an oral contraceptive tablet approved in 1974 as a small-molecule NDA by AbbVie. The product is a hormonal contraceptive indicated for prevention of pregnancy, containing progestin and estrogen in a 21-day active tablet regimen. It represents a mature, legacy oral contraceptive in a crowded therapeutic category.
LOE Approaching
Approaching loss of exclusivity signals potential team contraction or realignment; career progression opportunities may be limited as the brand transitions toward generic competition.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflect a mature, low-growth commercial profile with limited career acceleration potential. Professionals assigned to BREVICON 21-DAY should expect focus on retention, market defense, and smooth transition to generic era rather than product innovation or team expansion.
Brand ManagerProduct Manager
Worked on BREVICON 21-DAY at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.